CB Therapeutics Closes on Oversubscribed Series A
Retrieved on:
Monday, May 10, 2021
Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.
Key Points:
- Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.
- With this new funding, advisors, and the board, we aim to be the leading biotechnology company for the biosynthesis of tryptamines, cannabinoids, and their analogs.\xe2\x80\x9d\n\xe2\x80\x9cThis fresh round of funding for CB Therapeutics will allow us to rapidly accelerate our scaled up manufacturing and sale of cannabinoids and tryptamines,\xe2\x80\x9d said Dr. Jacob Vogan, CSO of CB Therapeutics.
- The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs.
- We seek out companies with innovative and highly impactful solutions to our global mental health crisis.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005112/en/\n'